This database contains 173 studies, archived under the term: "etiology"
Click here to filter this large number of results.
Use of the Tailored Activities Program to reduce neuropsychiatric behaviors in dementia: an Australian protocol for a randomized trial to evaluate its effectiveness
O'Connor, C. M.,
Clemson, L.,
Brodaty, H.,
Jeon, Y. H.,
Mioshi, E.,
Gitlin, L. N.
Background: Behavioral and psychological symptoms of dementia (BPSD) are often considered to be the greatest challenge in dementia care, leading to increased healthcare costs, caregiver burden, and placement into care facilities. With potential for pharmacological intervention to exacerbate behaviors or even lead to mortality, the development and rigorous testing of non-pharmacological interventions is vital. A […]
Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS)
Woolley, Susan C.,
York, Michele K.,
Moore, Dan H.,
Strutt, Adriana M.,
Murphy, Jennifer,
Schulz, Paul E.,
Katz, Jonathan S.
Up to half of patients with ALS develop cognitive impairment during the course of the illness. Despite this, there is no simple tool for screening patients in the clinical setting. This study examines the sensitivity, specificity and accuracy of the ALS Cognitive Behavioral Screen (ALS-CBS). We administered the measure to 112 ALS patients, including 31 […]
Midlife alcohol consumption and later risk of cognitive impairment: a twin follow-up study
Virtaa, Jyri J.,
Järvenpää, Tarja,
Heikkilä, Kauko,
Perola, Markus,
Koskenvuo, Markku,
Räihä, Ismo,
Rinne, Juha O.,
Kaprio, Jaakko
In this prospective follow-up study, we monitored the effects of midlife alcohol consumption and drinking patterns on cognitive impairment risks in late life. 1,486 subjects recruited from the Finnish Twin Cohort were included in the analyses. Alcohol consumption data was obtained with structured questionnaires in 1975 and 1981, and subjects were contacted between 1999 and […]
Midlife cardiovascular risk factors and late cognitive impairment
Virta, Jyri J.,
Heikkilä, Kauko,
Perola, Markus,
Koskenvuo, Markku,
Räihä, Ismo,
Rinne, Juha O.,
Kaprio, Jaakko
Cardiovascular risk factors increase the risk of dementia in later life. The aims of the current study were to assess the effect of multiple midlife cardiovascular risk factors on the risk of cognitive impairment in later life, and to assess the validity of the previously suggested CAIDE Study risk score predicting dementia risk 20 years later. […]
Cognitive rehabilitation changes memory-related brain activity in people with Alzheimer disease
van Paasschen, J.,
Clare, L.,
Yuen, K. S. L.,
Woods, R. T.,
Evans, S. J.,
Parkinson, C. H.,
Rugg, M. D.,
Linden, D. E. J.
Background: People with Alzheimer disease (AD) are capable of new learning when cognitive support is provided, suggesting that there is plasticity even in a degenerating brain. However, it is unclear how a cognition-focused intervention operates on a neural level.; Objective: The present study examined the effects of cognitive rehabilitation (CR) on memory-related brain activation in […]
Prevalence of anosognosia in Alzheimer’s disease
Turró-Garriga, Oriol,
Conde-Sala, Josep Lluís,
Reñé-Ramírez, Ramón,
López-Pousa, Secundino,
Gascón-Bayarri, Jordi,
Garre-Olmo, Josep
Background and Objective: Anosognosia is a disorder that affects the clinical presentation of Alzheimer’s disease (AD), increasing in frequency with the evolution of AD. The objective was to determine the prevalence of anosognosia and analyze the associated factors and predictors.; Patients and Method: Multicenter transversal and observational study of 345 AD patients. Anosognosia was assessed […]
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease
Trzepacz, Paula T.,
Cummings, Jeffrey,
Konechnik, Thomas,
Forrester, Tammy D.,
Chang, Curtis,
Dennehy, Ellen B.,
Willis, Brian A.,
Shuler, Catherine,
Tabas, Linda B.,
Lyketsos, Constantine
Background: Mibampator, an amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator, was evaluated for treatment of agitation and aggression (A/A) in Alzheimer’s disease (AD).; Methods: Outpatients (n = 132) with probable AD and A/A randomized to 12 weeks of double-blind treatment with 3-mg po mibampator or placebo were assessed using the 4-domain A/A subscale of the Neuropsychiatric Inventory […]